Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes

[1]  A. Noè,et al.  Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies , 2014, Cardiovascular Diabetology.

[2]  Andrea De Gaetano,et al.  Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[3]  C. Wouters,et al.  Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[4]  P. Libby,et al.  Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial , 2012, Circulation.

[5]  M. Donath,et al.  Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes , 2012, Diabetes Care.

[6]  H. Schumacher,et al.  Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions , 2012, Annals of the rheumatic diseases.

[7]  S. P. Parihar,et al.  Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. , 2011, Vaccine.

[8]  S. Shoelson,et al.  Type 2 diabetes as an inflammatory disease , 2011, Nature Reviews Immunology.

[9]  Christine E. Becker,et al.  Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes , 2010, Nature Immunology.

[10]  Xi Liu,et al.  Structural insights into the assembly and activation of IL-1β with its receptors , 2010, Nature Immunology.

[11]  G. Jennings,et al.  A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice , 2010, Virology Journal.

[12]  K. Maedler,et al.  XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. , 2010, Endocrinology.

[13]  G. Lacraz,et al.  IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat , 2009, Proceedings of the National Academy of Sciences.

[14]  S. Brownell,et al.  Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. , 2008, Cytokine.

[15]  L. Castellani,et al.  The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. , 2008, Endocrinology.

[16]  G. Jennings,et al.  Active immunization with IL‐1 displayed on virus‐like particles protects from autoimmune arthritis , 2008, European journal of immunology.

[17]  B. Ryffel,et al.  IL-1 Receptor-Mediated Signal Is an Essential Component of MyD88-Dependent Innate Response to Mycobacterium tuberculosis Infection , 2007, The Journal of Immunology.

[18]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[19]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[20]  A. Jegerlehner,et al.  A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. , 2002, Vaccine.

[21]  A. Simbirtsev,et al.  Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemothera , 2002 .

[22]  A. Simbirtsev,et al.  Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. II. Phase II study of the protective effect of recombinant human interleukin-1 beta on myelodepression induced by chemotherapy in cancer patients. , 2002, European cytokine network.

[23]  T. van der Poll,et al.  Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. , 2000, The Journal of infectious diseases.

[24]  Y. Iwakura,et al.  Protective Role of Interleukin-1 in Mycobacterial Infection in IL-1 α/β Double-Knockout Mice , 2000, Laboratory Investigation.

[25]  E. Hirsch,et al.  Effects of Interleukin-1 Receptor Antagonist Overexpression on Infection by Listeria monocytogenes , 1999, Infection and Immunity.

[26]  B. Brandhuber,et al.  Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1β , 1997, Nature.

[27]  J. Kurtzberg,et al.  A phase I trial of recombinant human interleukin-1β(OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation , 1997, Bone Marrow Transplantation.

[28]  S. Paul,et al.  Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Tonegawa,et al.  Presentation of endogenous viral proteins in association with major histocompatibility complex class II: On the role of intracellular compartmentalization, invariant chain and the TAP transporter system , 1995, European journal of immunology.

[30]  Y. Yoo,et al.  A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia , 1995, Infection and immunity.

[31]  J. Singer,et al.  Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. , 1994, Blood.

[32]  L. Moldawer,et al.  Type I IL-1 receptor blockade exacerbates murine listeriosis. , 1992, Journal of immunology.

[33]  M. Feinglos,et al.  Diet-Induced Type II Diabetes in C57BL/6J Mice , 1988, Diabetes.

[34]  P. Libby,et al.  Effects of Interleukin-1 Inhibition With Canakinumab on Hemoglobin A 1 c , Lipids , C-Reactive Protein , Interleukin-6 , and Fibrinogen A Phase IIb Randomized , Placebo-Controlled Trial , 2012 .

[35]  P. Libby,et al.  Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial , 2012, Circulation.

[36]  J. Stockman.  Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome , 2011 .

[37]  S. Schinner.  Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes , 2010 .

[38]  T. Wilkins,et al.  Infection in Mice , 2003 .

[39]  H. Joller-jemelka,et al.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.

[40]  A. Simbirtsev,et al.  Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemother , 2001, European cytokine network.

[41]  Y. Iwakura,et al.  Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. , 2000, Laboratory investigation; a journal of technical methods and pathology.

[42]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.